1. PO-15: Tinzaparin: a safe choice for lung cancer with VTE and renal impairment. Issue 213 (May 2022) Authors: Dimakakos, E.; Syrigos, K.N.; Vathiotis, I.; Tsiakos, K.; Anagnostakis, M.; Grammoustianou, M.; Gomatou, G.; Sarropoulou, F.; Gerotziafas, G.; Kotteas, E. Journal: Thrombosis research Issue: Issue 213(2022)Supplement 2 Page Start: S17 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PO-39: Superior vena cava stenting: an effective and safe therapeutic choice for the treatment of superior vena cava syndrome in lung cancer patients. Issue 213 (May 2022) Authors: Grammoustianou, M.; Syrigos, K.N.; Sarropoulou, F.; Patriarcheas, V.; Ptohis, N.; Charpidou, A.; Gkiozos, I.; Kouvela, M.; Gerotziafas, G.; Kainis, El; Kotteas, E.; Dimakakos, E. Journal: Thrombosis research Issue: Issue 213(2022)Supplement 2 Page Start: S29 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PO-40: Therapeutic approaches of superior vena cava syndrome in patients with non-small cell lung cancer (NSCLC). Issue 213 (May 2022) Authors: Dimakakos, E.; Grammoustianou, M.; Sarropoulou, F.; Kouvela, M.; Gkiozos, I.; Kotteas, E.; Gerotziafas, G.; Mavroudis, D.; Syrigos, K.N. Journal: Thrombosis research Issue: Issue 213(2022)Supplement 2 Page Start: S29 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗